Increased positive predictive values of agent efficacy were observed with PD-L1 expression cutoff value growth in urothelial cancer [63], non-small cell lung cancer (NSCLC) [64], and melanoma [65] treated with pembrolizumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.